

201 Chicago Avenue Minneapolis, Minnesota 55415 Tel: (612) 928-6100 Fax: (612) 454-2744

AAN.com **President** Carlayne E. Jackson, MD, FAAN *San Antonio, Texas* 

President Elect Natalia S. Rost, MD, MPH, FAAN, FAHA Boston, Massachusetts

Vice President Janis M. Miyasaki, MD, MEd, FRCPC, FAAN Edmonton, Alberta, Canada

> Sarah M. Benish, MD, FAAN Minneapolis, Minnesota

Treasurer Charles C. Flippen II, MD, FAAN Los Angeles, California

Immediate Past President Orly Avitzur, MD, MBA, FAAN Tarrytown, New York

Directors Wayne E. Anderson, DO, FAHS, FAAN San Francisco, California

Jennifer Bickel, MD, FAAN Tampa, Florida

Bruce H. Cohen, MD, FAAN Chair, Advocacy Committee Akron, Ohio

Gregory J. Esper, MD, MBA, FAAN Atlanta, Georgia

Larry B. Goldstein, MD, FAAN, FAHA Lexington, Kentucky

Lily Jung Henson, MD, MMM, FAAN Stockbridge, Georgia

> Shannon M. Kilgore, MD, FAAN Palo Alto, California

> Brad C. Klein, MD, MBA, FAAN Chair, Medical Economics and Practice Committee Abington, Pennsylvania

Jeffrey C. McClean II, MD, FAAN San Antonio, Texas

José G. Merino, MD, MPhil, FAHA, FAAN Editor-in-Chief, Neurology® Washington, DC

Nimish A. Mohile, MD, FAAN Chair, Diversity, Equity, and Inclusion Committee Rochester, New York

> Bruce I. Ovbiagele, MD, MSc, MAS, MBA, MLS, FAAN San Francisco, California

> > José H. Posas, MD, FAAN New Orleans, Louisiana

Maisha T. Robinson, MD, MSHPM, FAAN Chair, Member Engagement Committee Jacksonville, Florida

> Non-voting Board Member Mary E. Post, MBA, CAE Chief Executive Officer Minneapolis, Minnesota

June 25, 2024

The Honorable Assemblymember Bauer-Kahan 1020 N Street, Room 162 Sacramento, CA 95814

Dear Assemblymember Bauer-Kahan,

The American Academy of Neurology (AAN) is the world's largest association of neurologists and neuroscience professionals, with over 40,000 members. The AAN's mission is to enhance member career fulfillment and promote brain health for all. A neurologist is a doctor with specialized training in diagnosing, treating, and managing disorders of the brain and nervous system such as Alzheimer's disease, stroke, concussion, epilepsy, Parkinson's disease, multiple sclerosis, headache and migraine.

The AAN writes to express our support for SB 1223, which is a significant step towards protecting the privacy and autonomy of Californians in the face of advancing neurotechnology.

In recent years, the landscape of neurotechnology has grown substantially within the global marketplace. Innovations such as brain-computer interfaces (BCIs) and neurostimulation devices hold the promise of groundbreaking advancements, spanning from aiding individuals with neurological disabilities to augmenting cognitive abilities. This data is highly sensitive and without adequate safeguards, there is a risk of this data being exploited without the individual's consent.

While the California Consumer Privacy Act (CCPA) raised the bar for data protection standards, its scope falls short of explicitly addressing neural data. As the wearable neurotechnology market expands, this gap in regulation threatens patient privacy, with significant implications for the ethical handling of neural data.

SB 1223 would rectify this gap by classifying neural data as sensitive information under the CCPA. By furnishing precise definitions for neural data and neurotechnology, this bill provides much-needed clarity and guidance for both individuals and businesses.

On behalf of the AAN, our 40,000 members, and their patients, we urge a favorable vote on SB 1223. If you have any questions, please contact Grant Niver, Senior State Affairs Program Manager, at gniver@aan.com. Thank you for your consideration.

Sincerely,

Carlayne Jackson

Carlayne E. Jackson, MD, FAAN President, American Academy of Neurology